Related Experiment Video
Updated: May 22, 2026
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Prognoses of GEP-NETS with undetermined malignant potentials of their primary sites
Atsushi Kudo1, Daisuke Ban, Takumi Akashi
1Department of Hepatobiliary Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan. kudomsrg@tmd.ac.jp
Background/Aims:
In gastroenteropancreatic neuroendocrine tumors (GEP-NETs), primary lesions cannot be resected when the patients have highly advanced disease or when the primary sites are undefined. Such GEP-NETs cannot be evaluated with Ki-67 or the mitotic index. The aim of this study was to examine the prognosis of GEP-NETs that were ungraded by WHO G1-3 grading (U-NET group).
Methodology:
Between 2000 and 2011, 75 patients with sporadic GEP-NETs were treated at our institution. The prognosis of patients graded as new WHO grading (G-NET group) was compared with that of the U-NET group. Cox proportional hazard regression analyses were performed to estimate the risk factors for overall survival (OS).
Results:
Overall 1-, 3- and 5-year survival rates were 90.7%, 79.9% and 74.9%, respectively. The odds ratio (OR) of patients with synchronous liver metastasis and U-NET was 1.73 (p=0.01) and 5.84 (p=0.002), respectively. Multivariate analyses of OS according to baseline characteristics revealed the only independent risk factor to be U-NET (OR, 3.95; p=0.02).
Conclusions:
The malignant potential of U-NET may be no less than that of G-NET, while WHO-G3 patients have the worst prognoses in the G-NET group.
